TD Cowen Reiterates Buy Rating on Sutro Biopharma (STRO)

TD Cowen analyst Tara Bancroft reiterated a Buy rating on Sutro Biopharma (NASDAQ: STRO).

The analyst commented, "Luvelta+bev's 35% ORR in an unselected population and multiple doses is impressive on its own given that Elahere+bev had a 44% ORR in higher expressors at an optimal dose. The 56% ORR at the RP2D is even more exciting and could suggest broad use as it is competitive. Comprehensive data at the RP2D are expected in H1 which should continue to look great and solidify the next steps to registration."

For an analyst ratings summary and ratings history on Sutro Biopharma click here. For more ratings news on Sutro Biopharma click here.

Shares of Sutro Biopharma closed at $4.50 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Critical One Energy closes second tranche of flow-through placement
• Boeing lands two U.S. defense contracts worth over $711M